NCT00642720View on ClinicalTrials.gov

Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Quality of LifeAcromegaly
Interventions
DRUG

Pegvisomant

if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT00642720 - Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients | Biotech Hunter | Biotech Hunter